Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
about
The role of oxidative stress in Parkinson's diseaseParkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitroMutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodiesMitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synucleinDopamine-modified alpha-synuclein blocks chaperone-mediated autophagyParkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.Mouse models of Parkinson's disease associated with mitochondrial dysfunctionGenetically engineered mouse models of Parkinson's diseaseGene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian modelsSynucleins antagonize endoplasmic reticulum function to modulate dopamine transporter traffickingViable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synucleinAge-dependent effects of A53T alpha-synuclein on behavior and dopaminergic functionHuman A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neuronsAlpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicityThe contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseParkinson's disease: animal models and dopaminergic cell vulnerabilityGene-environment interactions: key to unraveling the mystery of Parkinson's diseaseResistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activationalpha-Synuclein produces a long-lasting increase in neurotransmitter releaseAltered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptorAlpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKIIIncreased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synucleinModelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT scoreAnimal models of Parkinson's disease: vertebrate geneticsHypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins.Genetic mouse models of parkinsonism: strengths and limitations.Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.A microarray study of MPP+-treated PC12 Cells: Mechanisms of toxicity (MOT) analysis using bioinformatics tools.Neuroanatomical phenotyping in the mouse: the dopaminergic system.Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease modelsLoss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons.Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathyThe chaperone-like activity of α-synuclein attenuates aggregation of its alternatively spliced isoform, 112-synuclein in vitro: plausible cross-talk between isoforms in protein aggregation.The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition.Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease.SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease
P2860
Q24307946-1499C3B4-21D3-4900-A4B8-7C1C12962150Q24311461-50B66E16-34F7-4D01-A698-29871D7E43C4Q24318474-E5501583-3312-4D2E-BD5B-400857C53F29Q24537310-62E5091F-596D-4AAC-887E-37A1A01F6670Q24683089-994B2113-B655-489C-AA75-7990C17228A3Q26269955-645A9300-CC08-4170-9AFF-62CD19696D4AQ26829851-E6BA3436-B7EE-4000-9BB3-C704744CFBF2Q26852964-DC790E41-1752-4B4D-93C8-9A266C6E0DDCQ26863375-6CF5C7C1-DA68-41ED-A384-1441431A0C40Q27310037-5EB9BBC6-4DFF-4DB5-836D-0BB4FC3B8FD0Q27311396-B1DFB506-1F1C-4630-BB42-A1C138345AC6Q27330366-099E5686-328C-481D-8C79-3C4BB3D669CBQ27332460-C8658284-B17D-489D-85DF-A4C59F93B828Q27934988-6DB6E92E-AB4B-428E-A4E1-DEE636D3F13FQ28068464-983DF18B-368A-48B8-8D39-D5C5D6F4111FQ28080503-FE320F42-29EB-491C-BED6-61DE9D6DE2D4Q28388674-591AA8F4-11DD-4853-82B8-EFF330A524FFQ28477043-15649463-FAA9-4FA0-A18E-753D6732069AQ28510893-ECBF9288-43AE-4CBF-9A89-95EBD8FAF26AQ28588013-74230173-B46D-49EB-813D-9052DDAB25ACQ28591581-62DAE3DF-7066-48A0-9804-B2C1275734B7Q28593809-3982F0E2-0E49-4DD4-A5DF-4477F5E309DCQ29048624-EB8C6BB4-0866-4227-8D62-8B4775D09A69Q30429583-5BB6E8B4-2956-44FB-B349-BC21B5554590Q30504583-51B8301F-E974-41C4-B6EB-C88266FB34C6Q30537732-01BD5BE4-D319-48EA-ACED-696CDED89EC5Q30895929-6DA61F89-4A3A-40B5-9DCA-BF7DD9D4BF2EQ33219784-F2BD1C75-0F0D-4992-A61D-277874ABD11FQ33227606-2A4D2E87-E87A-4841-8797-76B143545DEFQ33323265-71766791-E11C-4814-B039-D4EAA20CE9FBQ33392127-35B362DB-24D2-4D0B-9E8A-4F050D6E8A41Q33394700-0247AF44-FE17-4BF0-932F-A83D8EB208F2Q33521022-9372179D-4EC8-43DE-899E-C2EE7D0B4FFFQ33617563-95D70382-CE03-4117-8036-77738C0060B9Q33670282-F8FA58E6-1762-4714-9BDC-595BDA0A8575Q33707184-0F6BA15B-7F4A-41A6-A80D-22E6CC555C64Q33748087-E2B6917E-853C-4899-AD0B-E8B899A024BBQ33843073-7F8D8160-8134-4608-A9D7-2FD118D3B2CEQ33868426-385FB715-D2B3-4724-898B-C4D0D6B2161CQ33944220-942AC5A9-E5EB-4D0F-8396-AC1CFD09E5C9
P2860
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@ast
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@en
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@nl
type
label
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@ast
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@en
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@nl
prefLabel
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@ast
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@en
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@nl
P2093
P2860
P50
P356
P1476
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
@en
P2093
Anne-Cecile Trillat
Chao Annie Yuan
Kristin E Larsen
Marcelo Rocha
Miquel Vila
Nikolai Kholodilov
Robert Burke
Roland Staal
P2860
P304
14524-14529
P356
10.1073/PNAS.172514599
P407
P577
2002-10-10T00:00:00Z